Zacks: Brokerages Anticipate Jounce Therapeutics, Inc. (NASDAQ:JNCE) to Post -$0.57 EPS

Brokerages expect that Jounce Therapeutics, Inc. (NASDAQ:JNCEGet Rating) will post earnings of ($0.57) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Jounce Therapeutics’ earnings, with estimates ranging from ($0.62) to ($0.46). Jounce Therapeutics reported earnings per share of ($0.58) during the same quarter last year, which suggests a positive year over year growth rate of 1.7%. The company is scheduled to announce its next quarterly earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Jounce Therapeutics will report full year earnings of ($1.91) per share for the current financial year, with EPS estimates ranging from ($2.63) to ($0.92). For the next year, analysts anticipate that the business will post earnings of ($2.02) per share, with EPS estimates ranging from ($2.99) to ($1.16). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCEGet Rating) last announced its quarterly earnings results on Wednesday, March 2nd. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.36). During the same period in the prior year, the business posted $0.86 earnings per share.

A number of brokerages have recently commented on JNCE. Sumitomo Mitsui Financial Group began coverage on Jounce Therapeutics in a report on Wednesday, March 16th. They set an “outperform” rating and a $17.00 price objective on the stock. started coverage on Jounce Therapeutics in a research report on Thursday, March 31st. They issued a “sell” rating for the company. Finally, Cowen raised Jounce Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, February 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to, Jounce Therapeutics currently has a consensus rating of “Buy” and an average target price of $13.69.

Institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Jounce Therapeutics during the 1st quarter worth approximately $26,000. Royal Bank of Canada grew its position in Jounce Therapeutics by 77.2% in the third quarter. Royal Bank of Canada now owns 4,533 shares of the company’s stock worth $34,000 after acquiring an additional 1,975 shares in the last quarter. Citigroup Inc. lifted its stake in Jounce Therapeutics by 36.3% in the third quarter. Citigroup Inc. now owns 6,369 shares of the company’s stock worth $47,000 after purchasing an additional 1,696 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of Jounce Therapeutics by 184.8% during the third quarter. BNP Paribas Arbitrage SA now owns 9,406 shares of the company’s stock worth $70,000 after purchasing an additional 6,103 shares during the period. Finally, Metropolitan Life Insurance Co NY purchased a new stake in shares of Jounce Therapeutics during the third quarter worth about $71,000. Hedge funds and other institutional investors own 69.81% of the company’s stock.

Jounce Therapeutics stock traded down $0.45 during mid-day trading on Friday, hitting $5.30. The company’s stock had a trading volume of 194,398 shares, compared to its average volume of 445,283. Jounce Therapeutics has a 52-week low of $5.03 and a 52-week high of $9.81. The firm’s 50 day moving average is $6.87 and its 200 day moving average is $7.55. The company has a market cap of $273.85 million, a PE ratio of -2.88 and a beta of 1.02.

About Jounce Therapeutics (Get Rating)

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors.

Featured Stories

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with's FREE daily email newsletter.